Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05885503

Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema

A Phase III, Multicenter, Randomized, Double-blind, Active Controlled Trial of RC28-E Intravitreal Injection in Subjects With Diabetic Macular Edema

Status
Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
316 (estimated)
Sponsor
RemeGen Co., Ltd. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate efficacy and safety of RC28-E compared with Aflibercept in subjects with diabetic macular edema.

Conditions

Interventions

TypeNameDescription
BIOLOGICALRC-28EOphthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
BIOLOGICALAfliberceptOphthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.

Timeline

Start date
2023-06-08
Primary completion
2026-06-01
Completion
2026-06-01
First posted
2023-06-02
Last updated
2023-09-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05885503. Inclusion in this directory is not an endorsement.